<DOC>
	<DOCNO>NCT00960063</DOCNO>
	<brief_summary>This Phase 1/1B , non-randomized , open-label , dose-escalation study robatumumab ( SCH 717454 , MK-7454 ) administer combination chemotherapy pediatric participant solid tumor , conduct conformance Good Clinical Practices . This study evaluate safety , tolerability dose-finding robatumumab administer combination temozolomide irinotecan ( Arm A ) ; cyclophosphamide , doxorubicin , vincristine ( Arm B ) , ifosfamide etoposide ( Arm C ) . The primary study hypothesis robatumumab safely administer combination chemotherapy regimens pediatric participant solid tumor .</brief_summary>
	<brief_title>A Study Robatumumab ( SCH 717454 , MK-7454 ) Combination With Different Treatment Regimens Pediatric Participants With Advanced Solid Tumors ( P05883 , MK-7454-006 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Must &lt; = 21 year age ( old participant may allow study casebycase basis ) ; may either sex , race/ethnicity . Must histologic confirmation advance solid tumor , except brainstem tumor . Must Karnofsky performance score &gt; =50 ( participant &gt; 16 year age ) Lansky score &gt; 50 ( participant &lt; =16 year age ) . Must adequate organ function Screening . Must able adhere dose visit schedule . Must history another malignancy . Must uncontrolled diabetes mellitus . Must persistent , unresolved common terminology criterion adverse event ( CTCAE ) Grade &gt; =2 drugrelated toxicity associate previous treatment . Must know hypersensitivity antibody , accompany excipients associated medication . If female , must breastfeed , pregnant , intend become pregnant , positive pregnancy test Screening . Must know human immunodeficiency virus ( HIV ) infection know HIVrelated malignancy . Must know active Hepatitis B , Hepatitis C. Must serious uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>